Target intelligence / Profile preview

Ribosomal protein L17 pseudogene 51 (RPL17P51)

Target
RPL17P51
Molecular classification
Other (pseudogene), Not a member of any functional protein family such as "Receptor", "Enzyme", "Transporter", or "Transcription factor"
01

Overview

Ribosomal protein L17 pseudogene 51 (RPL17P51) is classified as a *processed pseudogene* derived from the ribosomal protein L17 gene (RPL17), which encodes a component of the large 60S ribosomal subunit essential for cellular protein synthesis[3][6]. Unlike RPL17, RPL17P51 does not encode a functional protein. Pseudogenes such as RPL17P51 arise through genomic duplication or retrotransposition events and typically lack protein-coding capability due to disruptive mutations, deletions, or truncations[6][7]. The vast majority of ribosomal protein pseudogenes—including RPL17P51—are biologically inactive, neither expressed nor involved in cellular processes, nor do they play a role as therapeutic targets[3][6][7]. While rare exceptions exist where specific pseudogenes can modulate gene expression or contribute to disease, no such function, interaction, or disease association has been established for RPL17P51.

Other names
RPL17P51Ribosomal protein L17 pseudogeneribosomal protein L17 pseudogene 51
02

Mechanism of action

Not applicable; no drugs or mechanisms as it is not a functional protein

03

Biological functions

No known biological function; as a pseudogene, RPL17P51 does not produce a protein and is generally not functionally active
04

Disease associations

None established; pseudogenes typically do not have roles in disease unless exceptionally reactivated or implicated by atypical mechanisms
05

Safety considerations

None; pseudogenes are generally biologically inert and have no known safety implications
06

Interacting drugs

None; as no protein product is produced, there are no known drugs interacting with RPL17P51
07

Biomarkers

None; this pseudogene is not used as a biomarker for patient selection or disease monitoring

Beyond the preview

Go deeper on Ribosomal protein L17 pseudogene 51 (RPL17P51).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L17 pseudogene 51 (RPL17P51).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call